Nuvalent Inc.
Nuvalent Announces Positive Pivotal Data for Neladalkib in ALK-positive NSCLC
Summary
On November 17, 2025, Nuvalent, Inc. announced positive topline pivotal data for neladalkib, its investigational ALK-selective inhibitor, in tyrosine kinase inhibitor (TKI) pre-treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from the global ALKOVE-1 Phase 1/2 clinical trial. The data showed an objective response rate (ORR) of 31% in the TKI pre-treated population, with encouraging results in specific subgroups, including patients with secondary ALK G1202R resistance mutations and those with active CNS disease. Neladalkib demonstrated a well-tolerated safety profile, with preliminary data suggesting increased incidence of transaminase elevations in less heavily pre-treated patients. The Company plans to discuss these results with the FDA and present detailed findings at a future medical meeting.
Profitelligence Alerts
Get alerts for NUVL
Be first to know when Nuvalent Inc. files with the SEC.
Filing Categories
Advertisement
About Nuvalent Inc.
Nuvalent Inc. is a biopharmaceutical company dedicated to the innovative development of small molecule therapies for cancer treatment. The company's primary focus is on creating targeted solutions for patients with cancer-related resistance mutations and treatment-related adverse effects. By leveraging their expertise in medicinal chemistry and deep understanding of tumor biology, Nuvalent aims to address significant gaps in current cancer therapies, particularly where existing treatments fall short due to resistance mechanisms. The company operates in a highly specialized sector that covers oncology research and development, presenting potential game-changing approaches within the broader pharmaceutical industry. Through its commitment to research and innovation, Nuvalent collaborates with leading research institutions to push the boundaries of what is achievable in cancer treatment. Situated within an ever-evolving market, the company plays a critical role in advancing new oncological solutions that may ultimately improve the quality of life for patients globally. Founded with the mission to transform patient care, Nuvalent's asset offerings are a testament to the progressive strides being made in next-generation cancer therapeutics.
Official SEC Documents
Advertisement